Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
BIOLIFE SOLUTIONS INC | 10%+ Owner | Common Stock, par value $.001 per share | 8.71 M | $153 M | $17.54 | Apr 30, 2024 | Direct |
MAXCYTE, INC. | 10%+ Owner | Common Stock, par value $0.01 per share | 10 M | $45.3 M | $4.53 | Oct 3, 2022 | Direct |
Verve Therapeutics, Inc. | 10%+ Owner | Common Stock | 2.42 M | $24.2 M | $10.00 | Jun 21, 2021 | Direct |
Absci Corp | Director | Common Stock | 6.75 M | $7.42 M | $1.10 | Jul 26, 2021 | Direct |
Tenaya Therapeutics, Inc. | 10%+ Owner | Common Stock | 362 K | $1.54 M | $4.26 | Aug 3, 2021 | Indirect |
Absci Corp | Director | Common Stock | 973 K | $1.07 M | $1.10 | Jul 26, 2021 | Indirect |
STANDARD BIOTOOLS INC. | Director, 10%+ Owner | Common Stock | 104 K | $212 K | $2.05 | Jun 18, 2024 | Direct |
BIOLIFE SOLUTIONS INC | 10%+ Owner | Common Stock, par value $.001 per share | 0 | $0 | $17.54 | Apr 30, 2024 | Indirect |
STANDARD BIOTOOLS INC. | Director, 10%+ Owner | Common Stock | 0 | $0 | $2.05 | Jun 18, 2024 | Indirect |
STANDARD BIOTOOLS INC. | Director, 10%+ Owner | Series B-1 Convertible Preferred Stock | 0 | $0 | $2.75 | Mar 18, 2024 | Indirect |
Absci Corp | Director | Convertible Note | 0 | Jul 26, 2021 | Direct | ||
Absci Corp | Director | Convertible Note | 0 | Jul 26, 2021 | Indirect | ||
Absci Corp | Director | Series E Preferred Stock | 0 | Jul 26, 2021 | Direct | ||
Tenaya Therapeutics, Inc. | 10%+ Owner | Series B Preferred Stock | 0 | Aug 3, 2021 | Indirect | ||
Tenaya Therapeutics, Inc. | 10%+ Owner | Series C Preferred Stock | 0 | Aug 3, 2021 | Indirect | ||
Verve Therapeutics, Inc. | 10%+ Owner | Series A-2 Preferred Stock | 0 | Jun 21, 2021 | Direct | ||
Verve Therapeutics, Inc. | 10%+ Owner | Series B Preferred Stock | 0 | Jun 21, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
LAB | STANDARD BIOTOOLS INC. | Jun 18, 2024 | 3 | $0 | 4 | Jun 21, 2024 | Director, 10%+ Owner |
LAB | STANDARD BIOTOOLS INC. | May 23, 2024 | 1 | $260 K | 4 | May 28, 2024 | Director, 10%+ Owner |
LAB | STANDARD BIOTOOLS INC. | May 20, 2024 | 3 | $1.54 M | 4 | May 22, 2024 | Director, 10%+ Owner |
LAB | STANDARD BIOTOOLS INC. | May 15, 2024 | 3 | $3.46 M | 4 | May 17, 2024 | Director, 10%+ Owner |
BLFS | BIOLIFE SOLUTIONS INC | Apr 30, 2024 | 2 | $0 | 4 | May 2, 2024 | 10%+ Owner |
LAB | STANDARD BIOTOOLS INC. | Mar 18, 2024 | 4 | $127 M | 4 | Mar 20, 2024 | Director, 10%+ Owner |
LAB | STANDARD BIOTOOLS INC. | Mar 4, 2024 | 2 | $646 K | 4 | Mar 6, 2024 | Director, 10%+ Owner |
LAB | STANDARD BIOTOOLS INC. | Jan 5, 2024 | 2 | $0 | 4 | Jan 9, 2024 | Director, 10%+ Owner |
BLFS | BIOLIFE SOLUTIONS INC | Oct 19, 2023 | 1 | $10.4 M | 4 | Oct 23, 2023 | 10%+ Owner |
BLFS | BIOLIFE SOLUTIONS INC | Aug 9, 2023 | 1 | $772 K | 4 | Aug 11, 2023 | 10%+ Owner |
BLFS | BIOLIFE SOLUTIONS INC | May 19, 2023 | 2 | $1.67 M | 4 | May 23, 2023 | 10%+ Owner |
LAB | STANDARD BIOTOOLS INC. | May 17, 2023 | 3 | $2.63 M | 4 | May 19, 2023 | Director, 10%+ Owner |
BLFS | BIOLIFE SOLUTIONS INC | May 16, 2023 | 3 | $1.59 M | 4 | May 18, 2023 | 10%+ Owner |
MXCT | MAXCYTE, INC. | Oct 3, 2022 | 1 | -$4.53 M | 4 | Oct 5, 2022 | 10%+ Owner |
MXCT | MAXCYTE, INC. | Jul 1, 2022 | 1 | -$13.9 M | 4 | Jul 6, 2022 | 10%+ Owner |
LAB | STANDARD BIOTOOLS INC. | Apr 4, 2022 | 1 | $0 | 4 | Apr 6, 2022 | Director, 10%+ Owner |
LAB | STANDARD BIOTOOLS INC. | Apr 4, 2022 | 0 | $0 | 3 | Apr 6, 2022 | Director |
BLFS | BIOLIFE SOLUTIONS INC | Sep 1, 2021 | 1 | $0 | 4/A | May 19, 2023 | 10%+ Owner |
TNYA | Tenaya Therapeutics, Inc. | Aug 3, 2021 | 6 | $12.8 M | 4 | Aug 4, 2021 | 10%+ Owner |
MXCT | MAXCYTE, INC. | Jul 30, 2021 | 1 | $23.4 M | 4 | Aug 3, 2021 | 10%+ Owner |
MXCT | MAXCYTE, INC. | Jul 29, 2021 | 0 | $0 | 3 | Jul 30, 2021 | 10%+ Owner |
TNYA | Tenaya Therapeutics, Inc. | Jul 29, 2021 | 0 | $0 | 3 | Jul 29, 2021 | 10%+ Owner |
ABSI | Absci Corp | Jul 26, 2021 | 7 | -$538 K | 4 | Jul 28, 2021 | Director |
ABSI | Absci Corp | Jul 21, 2021 | 0 | $0 | 3 | Jul 21, 2021 | Director, 10%+ Owner |
VERV | Verve Therapeutics, Inc. | Jun 21, 2021 | 5 | $20.9 M | 4 | Jun 22, 2021 | 10%+ Owner |
VERV | Verve Therapeutics, Inc. | Jun 16, 2021 | 0 | $0 | 3 | Jun 16, 2021 | 10%+ Owner |